PCM
CSTL icon

Perkins Capital Management’s Castle Biosciences CSTL Stock Holding History

Perkins Capital Management’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$385K Buy
16,140
+725
+5% +$16.1K 0.29% 61
2026
Q1 		$378K Sell
15,415
-12,630
-45% -$414K 0.35% 60
2025
Q4 		$1.09M Sell
28,045
-100
-0.4% -$3.22K 0.87% 37
2025
Q3 		$641K Buy
28,145
+150
+0.5% +$3.05K 0.56% 47
2025
Q2 		$572K Sell
27,995
-5,970
-18% -$111K 0.57% 44
2025
Q1 		$680K Sell
33,965
-200
-0.6% -$4.95K 0.72% 44
2024
Q4 		$910K Buy
34,165
+1,525
+5% +$46.4K 0.81% 41
2024
Q3 		$931K Buy
32,640
+1,550
+5% +$39.5K 0.87% 37
2024
Q2 		$677K Sell
31,090
-1,050
-3% -$23.4K 0.64% 47
2024
Q1 		$712K Hold
32,140
– – 0.59% 51
2023
Q4 		$694K Buy
32,140
+2,980
+10% +$52.4K 0.59% 52
2023
Q3 		$493K Sell
29,160
-1,425
-5% -$24.9K 0.49% 59
2023
Q2 		$420K Sell
30,585
-525
-2% -$10.6K 0.37% 64
2023
Q1 		$707K Hold
31,110
– – 0.67% 48
2022
Q4 		$732K Hold
31,110
– – 0.77% 39
2022
Q3 		$811K Sell
31,110
-2,060
-6% -$57.8K 0.91% 37
2022
Q2 		$728K Hold
33,170
– – 0.75% 48
2022
Q1 		$1.49M Hold
33,170
– – 1.22% 32
2021
Q4 		$1.42M Buy
33,170
+20
+0.1% +$1.04K 0.96% 37
2021
Q3 		$2.2M Hold
33,150
– – 1.36% 25
2021
Q2 		$2.43M Sell
33,150
-350
-1% -$23.1K 1.38% 26
2021
Q1 		$2.29M Sell
33,500
-1,000
-3% -$75.2K 1.33% 26
2020
Q4 		$2.32M Sell
34,500
-400
-1% -$21.7K 1.52% 19
2020
Q3 		$1.8M Buy
+34,900
New +$1.55M 1.65% 19
2020
Q1 		$1.01M Buy
33,850
+6,455
+24% +$195K 1.22% 28
2019
Q4 		$942K Sell
27,395
-525
-2% -$12.8K 0.84% 41
2019
Q3 		$505K Buy
+27,920
New +$619K 0.44% 69

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $112B AUM 36.28% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perkins Capital Management's CSTL Position: Q2 2026 in Review

Perkins Capital Management increased its Castle Biosciences (CSTL) stake by 4.7% in Q2 2026, buying an estimated $16.1K and bringing the position to 16,140 shares worth $385K. The position accounts for 0.29% of the portfolio, ranked #61.

Perkins Capital Management first reported a position in CSTL in Q3 2019 and has held it in 27 quarters since. The position peaked at $2.43M in Q2 2021. 176 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Perkins Capital Management held 16,140 shares of Castle Biosciences worth $385K as of Q2 2026.
  • Perkins Capital Management bought 725 Castle Biosciences shares in Q2 2026, an estimated $16.1K.
  • Castle Biosciences made up 0.29% of Perkins Capital Management's portfolio in Q2 2026, its #61 holding.
  • Perkins Capital Management first reported a position in Castle Biosciences in Q3 2019 and has held it in 27 quarters since.
  • Perkins Capital Management's Castle Biosciences position peaked at $2.43M in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Perkins Capital Management's 13F filing for Q2 2026, filed 24 Jul 2026.